Abnormal uterine Bleeding

AUB

Normal Menstruation

Normal Menstruation

Menstruation is a natural, hormone-driven process in which the lining of the uterus (endometrium) is shed each month when pregnancy does not occur. This cycle is regulated mainly by the hormones oestrogen and progesterone.

A typical menstrual cycle lasts around 28 days, (24-38 days) with bleeding for 4–5 days (2-7 days) with a blood loss of 5–80 mL.

What Happens During a Period

  • The upper layer of the uterine lining breaks down and is shed

  • Blood vessels constrict and then reopen, contributing to bleeding

  • Inflammatory and repair processes are activated

  • The uterus contracts (often felt as cramps) to help expel menstrual tissue

Mechanisms That Stop Menstrual Bleeding

The body uses several coordinated processes to stop menstrual bleeding:

  • Uterine contractions: Help compress blood vessels and reduce blood flow

  • Vasoconstriction: Narrowing of endometrial blood vessels limits bleeding

  • Endometrial repair: Rapid healing and regeneration of the uterine lining restore normal surface integrity

These mechanisms work together to ensure bleeding remains controlled and self-limited.

How the Cycle Works

  • Build-up phase (proliferative phase):

    Oestrogen stimulates the uterine lining to thicken and prepare for possible pregnancy.

  • Post-ovulation (secretory phase):

    Progesterone stabilises and matures the lining, making it suitable for embryo implantation.

  • Menstruation:

    If pregnancy does not occur, hormone levels fall—especially progesterone—triggering shedding of the lining

Repair and Regeneration

After shedding, the lining rapidly repairs and regenerates from deeper layers, preparing for the next cycle.

Normal menstruation depends on a delicate balance of hormonal, vascular, and immune processes. Disruption of any of these can lead to abnormal bleeding patterns.

Abnormal Uterine Bleeding

Any deviation from the above parameters is considered Abnormal uterine bleeding (AUB). The latter refers to any variation in menstrual cycle frequency, regularity, duration, or volume in non-pregnant women of reproductive age. Up to one-third of women experience AUB, particularly around menarche and perimenopause.

Assessment & Management

Evaluation includes a detailed history, examination, and appropriate investigations (blood tests, imaging, or endometrial sampling). Treatment is tailored to the underlying cause, severity, and patient preferences, with the aim of controlling bleeding and improving quality of life.

Classification

Modern classification (FIGO) improves clarity and includes:

  • Descriptive terms:

    • Heavy menstrual bleeding (HMB)

    • Intermenstrual bleeding

    • Breakthrough bleeding (on hormonal therapy)

  • Causes (PALM-COEIN):

    • Structural: Polyp, adenomyosis, fibroids (leiomyoma), malignancy/hyperplasia

    • Non-structural: Coagulopathy, ovulatory dysfunction, endometrial, iatrogenic, other

  • Types

  • Acute AUB: Sudden, heavy bleeding requiring urgent management

  • Chronic AUB: Irregular bleeding present for most of the past 6 months

Classification of AUB

PALM-COEIN

The FIGO PALM-COEIN system categorises causes of abnormal uterine bleeding into structural and non-structural groups to guide diagnosis and management.

Structural Causes (PALM)

  • Polyp (P): Benign growths that may cause intermenstrual bleeding

  • Adenomyosis (A): Endometrial tissue within the uterine muscle, causing heavy, painful periods

  • Leiomyoma (L): Fibroids that may lead to heavy or prolonged bleeding

  • Malignancy/Hyperplasia (M): Abnormal or cancerous changes of the endometrium, often with irregular bleeding

AUB is often multifactorial, requiring a tailored, patient-specific approach combining clinical assessment, imaging, and laboratory evaluation.

Abnormal uterine bleeding (AUB) is common among reproductive-aged women, with an estimated prevalence of 3% to 30%, increasing to 35% or more when irregular and intermenstrual bleeding are included.

Rates are higher around menarche and perimenopause. Heavy menstrual bleeding (HMB) alone affects up to 27% of women in Europe, with some global estimates exceeding 50%.

True prevalence is likely underestimated, as many women do not seek medical care and symptom reporting can be both subjective and variable.

Non-Structural Causes (COEIN)

  • Coagulopathy (C): Bleeding disorders (e.g. von Willebrand disease)

  • Ovulatory dysfunction (O): Irregular ovulation (e.g. PCOS, thyroid disorders)

  • Endometrial (E): Disorders affecting the lining’s ability to control bleeding

  • Iatrogenic (I): Medication- or treatment-related (e.g. hormonal therapy, anticoagulants)

  • Not otherwise classified (N): Less common causes (e.g. vascular abnormalities)

Why Does Abnormal Uterine Bleeding Happen?

During a normal menstrual cycle, the build-up and shedding of the uterine lining are tightly regulated by hormones in a coordinated manner. When this hormonal balance is disrupted, bleeding may become heavier, irregular, or prolonged.

AUB can also occur when the body’s natural mechanisms that control bleeding—particularly uterine contractions and blood vessel constriction—are impaired.

In many cases, more than one factor is involved. Identifying the underlying cause is key to effective, personalised treatment.

Common causes include:

  • Hormonal imbalance: Irregular ovulation can lead to excessive build-up of the lining and unpredictable shedding

  • Endometrial (lining) dysfunction: The lining may not regulate bleeding or repair effectively

  • Structural conditions: Fibroids or adenomyosis can affect uterine contractions and blood flow

Conditions that increase pelvic or uterine congestion:

  • Pelvic congestion syndrome (enlarged pelvic veins)

  • Fibroids or adenomyosis increasing uterine blood supply

  • Chronic inflammation (e.g. endometriosis or pelvic inflammatory disease)

Bleeding (clotting) disorders:

  • Conditions such as von Willebrand disease or other clotting abnormalities can lead to heavier or prolonged bleeding due to impaired blood clotting

Assessment of Abnormal Uterine Bleeding (AUB)

A thorough clinical assessment is essential to identify the cause and evaluate the impact of abnormal uterine bleeding.

Also, a structured, patient-centred approach ensures accurate diagnosis and supports a tailored management plan.

Initial Assessment

  • Assess hemodynamic stability first in cases of heavy or acute bleeding

  • Stabilise the patient if required before further evaluation

Clinical History

A detailed history typically includes the following:

Menstrual history

  • Age at first period (menarche)

  • Last menstrual period

  • Cycle pattern: frequency, regularity, duration, and flow

  • Indicators of heavy bleeding (e.g. frequent pad/tampon changes, clots, flooding, night changes, impact on daily life)

  • Intermenstrual or postcoital bleeding

Associated symptoms

  • Pelvic pain

  • Vaginal discharge

  • Bowel or bladder symptoms

  • Symptoms of anaemia (fatigue, dizziness)

  • Features of hormonal or endocrine disorders

Reproductive and sexual history

  • Previous pregnancies and mode of delivery

  • Fertility wishes or subfertility

  • Current contraception

  • History of sexually transmitted infections

  • Cervical screening (smear) history

Medical and social history

  • Current medications

  • Personal or family history of bleeding disorders, endocrine conditions, or malignancy

  • Lifestyle factors (smoking, alcohol, drugs)

  • Impact on quality of life

Physical Examination in AUB

A focused physical examination helps identify the cause and assess severity.

This structured examination supports accurate diagnosis and guides further investigations and management.

Initial Assessment

  • Check for hemodynamic instability

    • Low blood pressure

    • Rapid pulse)

Endocrine Features

  • Thyroid examination (enlargement or tenderness)

  • Signs of hormonal imbalance, such as:

    • Excess hair growth or acne (suggesting androgen excess)

    • Features of Cushing’s syndrome (e.g. central weight gain, striae)

General Examination

  • Vital signs, including blood pressure and BMI

  • Signs of anaemia (pallor) or bleeding disorders (bruising, petechiae)

  • In adolescents, assessment of pubertal development

Abdominal and Pelvic Examination

  • Abdominal palpation for masses

  • Pelvic examination (speculum and bimanual) where appropriate

  • Cervical screening and tests for infections if indicated

Evaluation of Abnormal Uterine Bleeding (AUB)

Assessment of AUB involves a combination of blood tests, imaging, and sometimes endometrial sampling to identify the cause and guide treatment.

A structured evaluation helps distinguish between causes and ensures tailored, effective management.

Imaging

  • Ultrasound (transvaginal or abdominal) – first-line to assess structural causes (e.g. fibroids, polyps, adenomyosis)

  • Sonohysterography – improves detection of abnormalities داخل the uterine cavity

  • MRI – reserved for complex or unclear cases

Laboratory Tests

  • Pregnancy test (essential in all reproductive-age women)

  • Full blood count (CBC) to check for anaemia

Additional tests (if indicated):

  • Thyroid function – if symptoms suggest thyroid disease

  • Hormonal tests – if endocrine causes are suspected

  • Bleeding disorder screen – especially with heavy or long-standing bleeding

  • Ferritin – to assess iron stores

  • Blood grouping/crossmatch – in severe bleeding cases

Endometrial Assessment

  • Endometrial biopsy recommended:

    • Age ≥45 years

    • Persistent or unexplained bleeding

    • Risk factors for endometrial cancer

    • Failed medical treatment

  • Hysteroscopy may be needed if biopsy is inconclusive or symptoms persist

.Treatment of Abnormal Uterine Bleeding (AUB)

Management depends on the cause, severity of bleeding, fertility wishes, and overall health. Treatment is recommended when bleeding causes anaemia or significantly affects quality of life.

A personalised, stepwise approach ensures effective symptom control while aligning with the patient’s preferences and reproductive goals.

Acute (Emergency) Management

For severe or unstable bleeding:

  • Hospital admission may be required

  • Medical treatment:

    • High-dose hormonal therapy (oestrogen, combined pill, or progestins)

    • Tranexamic acid to reduce bleeding

  • Supportive care:

    • IV fluids, antiemetics, iron

  • Procedures (if needed):

    • Uterine tamponade (balloon/catheter)

    • Rarely surgery (e.g. curettage, embolisation, hysterectomy)

Long-Term Management

  • Ongoing hormonal therapy to regulate cycles

  • Iron supplementation if anaemia is present

  • In selected cases: GnRH analogues (with add-back therapy)

Surgical Options

Considered if medical treatment fails or is not suitable:

  • Hysteroscopy (polyp removal)

  • Myomectomy (fibroid removal)

  • Endometrial ablation (not suitable if future fertility desired)

  • Uterine artery embolisation

  • Hysterectomy (definitive treatment)

Non-Emergency (Routine) Treatment

Hormonal options

  • Hormonal coil (Mirena/LNG-IUD) – most effective for reducing bleeding

  • Combined oral contraceptive pill – regulates cycles and reduces flow

  • Progestin-only treatments – oral or injectable

Non-hormonal options

  • Tranexamic acid – reduces blood loss during periods

  • NSAIDs (e.g. ibuprofen) – reduce bleeding and pain

Management Based on Cause (PALM-COEIN)

Treatment of abnormal uterine bleeding is tailored to the underlying cause.

Management is individualised, balancing effectiveness, side effects, fertility wishes, and patient preference.

Imaging

  • Ultrasound (transvaginal or abdominal) – first-line to assess structural causes (e.g. fibroids, polyps, adenomyosis)

  • Sonohysterography – improves detection of abnormalities داخل the uterine cavity

  • MRI – reserved for complex or unclear cases

Structural Causes (PALM)

  • Polyps (P)

    • Surgical removal (hysteroscopic resection)

  • Adenomyosis (A)

    • Definitive: hysterectomy

    • Selected cases: conservative surgery or hormonal therapy

  • Fibroids / Leiomyomas (L)

    • Medical: hormonal coil, GnRH analogues, progestins, tranexamic acid, NSAIDs

    • Surgical: myomectomy, uterine artery embolisation, endometrial ablation, or hysterectomy

  • Malignancy / Hyperplasia (M)

    • Primarily surgical management ± additional therapies (e.g. hormonal or radiotherapy)

    • Non-surgical options (e.g. high-dose progestins) in selected cases

Non-Structural Causes (COEIN)

  • Coagulopathies (C)

    • Tranexamic acid or desmopressin (DDAVP)

  • Ovulatory Dysfunction (O)

    • Treat underlying cause (e.g. PCOS, thyroid disorders)

    • Lifestyle changes and hormonal regulation

  • Endometrial Causes (E)

    • Managed symptomatically (no specific targeted therapy)

  • Iatrogenic (I)

    • Adjust or change causative medication

    • Consider alternative contraception if needed

  • Not Otherwise Classified (N)

    • Treat underlying condition (e.g. antibiotics for infection, embolisation for vascular issues)